Transdermal delivery system for dried particulate or lyophilized medications
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61L-015/16
A61N-001/30
A61K-038/28
출원번호
US-0327016
(2006-01-05)
등록번호
US-7363075
(2008-04-22)
우선권정보
IL-152574(2002-10-31)
발명자
/ 주소
Stern,Meir
Levin,Galit
출원인 / 주소
TransPharma Medical Ltd.
대리인 / 주소
Winston & Strawn LLP
인용정보
피인용 횟수 :
21인용 특허 :
32
초록▼
The present invention provides a system for transdermal delivery of dried or lyophilized pharmaceutical compositions and methods using thereof. The system comprises an apparatus for facilitating transdermal delivery of an agent that generates hydrophilic micro-channels, and a patch comprising a the
The present invention provides a system for transdermal delivery of dried or lyophilized pharmaceutical compositions and methods using thereof. The system comprises an apparatus for facilitating transdermal delivery of an agent that generates hydrophilic micro-channels, and a patch comprising a therapeutically active agent. The present invention is useful for transdermal delivery of hydrophilic agents, particularly of high molecular weight proteins.
대표청구항▼
The invention claimed is: 1. A system for transdermal delivery of a peptide or polypeptide from a dried pharmaceutical composition comprising: (i) an apparatus for facilitating transdermal delivery of a peptide or polypeptide through skin of a subject, said apparatus comprises: (a) an electrode car
The invention claimed is: 1. A system for transdermal delivery of a peptide or polypeptide from a dried pharmaceutical composition comprising: (i) an apparatus for facilitating transdermal delivery of a peptide or polypeptide through skin of a subject, said apparatus comprises: (a) an electrode cartridge comprising at least one electrode; and (b) a main unit comprising a control unit which is adapted to apply electrical energy to the electrode when the electrode is in vicinity of the skin, typically generating current flow or one or more sparks, enabling ablation of stratum corneum in an area beneath the electrode, thereby generating at least one micro-channel in the area on the skin of the subject; and (ii) a patch comprising a non-adhesive liner and a dried pharmaceutical composition comprising a peptide or polypeptide having up to two hundred amino acid residues, wherein the dried pharmaceutical composition is present upon the non-adhesive liner. 2. The system according to claim 1, wherein the peptide is calcitonin. 3. The system according to claim 2, wherein the peptide is salmon calcitonin. 4. The system according to claim 1, wherein the peptide is parathyroid hormone (PTH). 5. The system according to claim 4, wherein the peptide is human PTH (hPTH). 6. The system according to claim 5, wherein the peptide is hPTH (1-34). 7. The system according to claim 1, wherein the pharmaceutical composition further comprises a stabilizer. 8. The system according to claim 7, wherein the stabilizer is a carbohydrate selected from the group consisting of glucose, galactose, raffinose, cellobiose, gentiobiose, sucrose and trehalose. 9. The system according to claim 1, wherein the pharmaceutical composition further comprises an acidic component to yield a pH in the range from about 3 to about 6 in solution before drying. 10. The system according to claim 9, wherein the pharmaceutical composition comprises hPTH (1-34), sucrose and acetic acid to yield a pH of about 4.0 in solution before drying. 11. The system according to claim 9, wherein the pharmaceutical composition comprises hPTH (1-34), trehalose and citric acid to yield a pH of about 4.0 in solution before drying. 12. The system of claim 1, wherein the patch is a printed patch comprising a uniform distribution of dried solid dots of the pharmaceutical composition present upon the non-adhesive liner. 13. The system according to claim 12, wherein the peptide is calcitonin. 14. The system according to claim 13, wherein the peptide is salmon calcitonin. 15. The system according to claim 12, wherein the peptide is parathyroid hormone (PTH). 16. The system according to claim 15, wherein the peptide is human PTH (hPTH). 17. The system according to claim 16, wherein the peptide is hPTH (1-34). 18. The system according to claim 12, wherein the pharmaceutical composition further comprises a stabilizer. 19. The system according to claim 18, wherein the stabilizer is a carbohydrate selected from the group consisting of glucose, galactose, raffinose, cellobiose, gentiobiose, sucrose and trehalose. 20. The system according to claim 12, wherein the pharmaceutical composition further comprises an acidic component to yield a pH in the range from about 3 to about 6 in solution before drying. 21. The system according to claim 20, wherein the pharmaceutical composition comprises hPTH (1-34), sucrose and acetic acid to yield a pH of about 4.0 in solution before drying. 22. The system according to claim 20, wherein the pharmaceutical composition comprises hPTH (1-34), trehalose and citric acid to yield a pH of about 4.0 in solution before drying. 23. A method for transdermal administration of a dried pharmaceutical composition comprising a peptide or polypeptide by the system of claim 1, the method comprising: (a) generating at least one micro-channel in an area of the skin of a subject by the apparatus, and (b) affixing the patch upon the micro-channel generated area to administer the pharmaceutical composition by dissolving it in fluids that are exuded from the skin through the micro-channel(s). 24. The method according to claim 23 further comprising: (c) achieving a therapeutic blood concentration of the peptide or polypeptide for a predetermined period of time. 25. The method according to claim 23, wherein the peptide is calcitonin. 26. The method according to claim 25, wherein the peptide is salmon calcitonin. 27. The method according to claim 23, wherein the peptide is parathyroid hormone (PTH). 28. The method according to claim 27, wherein the peptide is human PTH. 29. The method according to claim 28, wherein the peptide is hPTH (1-34). 30. The system according to claim 1, wherein the electrode cartridge is removable. 31. The system according to claim 1, wherein the electrode cartridge comprises a plurality of electrodes. 32. The system according to claim 1, wherein the electrical energy is at radio frequency. 33. The method according to claim 23, wherein the pharmaceutical composition further comprises a stabilizer. 34. The method according to claim 33, wherein the stabilizer is a carbohydrate selected from the group consisting of glucose, galactose, raffinose, cellobiose, gentiobiose, sucrose and trehalose. 35. The method according to claim 23, wherein the pharmaceutical composition further comprises an acidic component to yield a pH in the range from about 3 to about 6 in solution before drying. 36. The method according to claim 35, wherein the pharmaceutical composition comprises hPTH (1-34), sucrose and acetic acid to yield a pH of about 4.0 in solution before drying. 37. The method according to claim 35, wherein the pharmaceutical composition comprises hPTH (1-34), trehalose and citric acid to yield a pH of about 4.0 in solution before drying. 38. The method according to claim 23, wherein the patch is a printed patch comprising a uniform distribution of dried solid dots of the pharmaceutical composition present on the non-adhesive liner. 39. The method according to claim 38, wherein the peptide is calcitonin. 40. The method according to claim 39, wherein the peptide is salmon calcitonin. 41. The method according to claim 38, wherein the peptide is parathyroid hormone (PTH). 42. The method according to claim 41, wherein the peptide is human PTH (hPTH). 43. The method according to claim 42, wherein the peptide is hPTH (1-34). 44. The method according to claim 38, wherein the pharmaceutical composition further comprises a stabilizer. 45. The method according to claim 44, wherein the stabilizer is a carbohydrate selected from the group consisting of glucose, galactose, raffinose, cellobiose, gentiobiose, sucrose and trehalose. 46. The method according to claim 38, wherein the pharmaceutical composition further comprises an acidic component to yield a pH in the range from about 3 to about 6 in solution before drying. 47. The method according to claim 46, wherein the pharmaceutical composition comprises hPTH (1-34), sucrose and acetic acid to yield a pH of about 4.0 in solution before drying. 48. The method according to claim 46, wherein the pharmaceutical composition comprises hPTH (1-34), trehalose and citric acid to yield a pH of about 4.0 in solution before drying.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (32)
Haralambopoulos Constantine ; Ryan Paul, Adhesive matrix type transdermal patch and method of manufacturing same.
Eppstein Jonathan A. ; Hatch Michael R., Apparatus and method for electroporation of microporated tissue for enhancing flux rates for monitoring and delivery applications.
Weaver James C. (Sudbury MA) Powell Kevin T. (Boston MA) Langer ; Jr. Robert S. (Newton MA), Control of transport of molecules across tissue using electroporation.
Lattin Gary A. (Forest Lake MN) Dickson Dale A. (Fridley MN) Grace Michael J. (Coon Rapids MN), Electrotransport agent delivery device having a disposable component and a removable liner.
Brown ; III Charles L. ; Crawford Neville,GBX ; Freear Steven,GBX, Iontophoresis, electroporation and combination catheters for local drug delivery to arteries and other body tissues.
Haak Ronald P. (San Jose CA) Gyory J. Richard (San Jose CA) Theeuwes Felix (Los Altos CA) Landrau Felix A. (San Jose CA) Roth Nathan (San Francisco CA) Myers Robert M. (Stanford CA), Iontophoretic delivery device and method of hydrating same.
Haak Ronald P. ; Gyory J. Richard ; Myers Robert M. ; Landrau Felix A. ; Sanders Harold F. ; Kleiner Lothar W. ; Hearney Linda M., Iontophoretic drug delivery apparatus.
Haak Ronald P. ; Meyers Robert M. ; Landrau Felix A. ; Sanders Harold F. ; Kleiner Lothar W. ; Gyory J. Richard, Iontophoretic drug delivery apparatus.
M.ang.rin Per,SEX, Preparation for the treatment of metabolic syndrome containing human growth hormone in combination with a cortisol synthesis inhibitor.
Horstmann Michael (Neuwied DEX) Herrmann Fritz (Neuwied DEX), Transdermal therapeutic system exhibiting an increased active substance flow and process for the production thereof.
DiPerna, Paul M.; Brown, David; Rosinko, Mike; Kincade, Dan; Michaud, Michael; Nadworny, John; Kruse, Geoffrey A.; Ulrich, Thomas R., Infusion pump system with disposable cartridge having pressure venting and pressure feedback.
DiPerna, Paul M.; Brown, David; Rosinko, Mike; Kincade, Dan; Michaud, Michael; Nadworny, John; Kruse, Geoffrey A.; Ulrich, Thomas R., Infusion pump system with disposable cartridge having pressure venting and pressure feedback.
Verhoef, Erik T.; DiPerna, Paul M.; Rosinko, Mike; Williamson, Mark; Kruse, Geoffrey A.; Ulrich, Thomas R.; Lamb, Phil; Saint, Sean; Michaud, Michael; Trevaskis, William, Infusion pump system with disposable cartridge having pressure venting and pressure feedback.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.